GlaxoSmithKline Says EU Approves Long-Acting HIV Treatment
21 Diciembre 2020 - 2:00AM
Noticias Dow Jones
By Anthony O. Goriainoff
GlaxoSmithKline PLC said Monday that the EU has granted
marketing authorization for ViiV Healthcare's long-acting HIV
treatment Vocabria.
The British pharmaceutical company said that majority-owned ViiV
Healthcare announced the authorization of Vocabria in combination
with Janssen Pharmaceutical Companies of Johnson & Johnson's
Rekambys and Edurant for the treatment of HIV-1 infection in
adults.
The company said Vocabria could potentially change the treatment
experience for some people living with HIV as it removes the need
for daily HIV tablets and can reduce the days they receive
treatment from 365 to 12 or six per year.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
December 21, 2020 02:45 ET (07:45 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
